Credits: AP, TradeIndia
US President Donald Trump held a press conference to announce the connection between the use of Tylenol, a popular pain and fever relief medicine during pregnancy and autism. Trump in the press conference also suggested Leucovorin, as a potential treatment for autism symptom.
Read: Tylenol And Autism: Trump Announces Link Between The Two, Science Does Not Back Him
It is known as folinic acid, a form of folate, also an essential B vitamin or B9, which has been approved by the US Food and Drug Administration (FDA) for counteracting the toxic effects of certain cancer drugs. It can counteract methotrexate that blocks body's use of folate.
The drug is also used to enhance the effects of chemotherapy drugs and to treat specific types of anemia.
The drug can be administered orally or intravenously. While it is manufactured by dozens of companies, notes US FDA, on Monday itself, FDA published a notice to the Federal Register ahead of Trump's press conference to approve a version of Leucovorin manufactured by GlaxoSmithKline or GSK.
GSK had previously withdrawn from FDA's consideration when it stopped making the drug. However, as per the FDA notice, "The FDA is working with GSK, the innovator of Wellcovorin (leucovorin calcium), on a process to include the essential scientific information needed for the safe and effective use of these drug products for adults and pediatric patients with CFD (cerebral folate deficiency)."
As per the FDA notice, leucovorin calcium, branded as Wellcovorin by GSK is sent for approval for patients with cerebral folate deficiency, which is a neurological condition that affects folate, an essential vitamin for brain health, transport into the brain.
The FDA notice mentions that individuals with CFD have been "observed to have developmental delays with autistic features".
FDA Commissioner Marty Makary, MF, MPH said that in over two decades, the US has "witnessed a tragic four-fold increase in autism". He further noted: "Children are suffering and deserve access to potential treatments that have shown promise. We are using gold standard science and common sense to deliver for the American people.”
George Tidmarsh, MD, PhD, Director of the FDA's Center for Drug Evaluation and Research said that FDA is collaborating with GSK to broaden the existing Wellcovorin label and is committed to "finding and treating the root causes of autism".
Read: Trump's Claim On Linking Tylenol And Autism Is Unscientific, According To Doctors
Doctors have been using leucovorin off-label for autism, repurposing the drug beyond its original approval, reported Reuters.
Research from SUNY Downstate Medical Center and others suggests that as many as three-quarters of children with autism may have genetic variations or autoimmune issues that interfere with folate processing in the brain.
Smaller studies have linked these problems to more severe autism symptoms and found that leucovorin treatment may help improve speech, social interaction, and irritability. Still, the Autism Science Foundation cautions that the research is in its early stages, and more evidence is needed before firm conclusions can be drawn.
Read: Trump Suggests Changes In Childhood Vaccines, Says It Is Based On What He Feels
A 2016 study published in Molecular Psychiatry, which was a randomized controlled trial suggested that this specialized form of folate can improve communication and language skills in some children with Autism Spectrum Disorder (ASD).
A June 2020 study published in the Seminars in Pediatric Neurology suggests folate (vitamin B9) plays a vital role in brain development and function, helping with DNA synthesis, methylation, and neurotransmitter production. Some children with autism struggle with folate metabolism, particularly in transporting folate into the brain, a condition known as cerebral folate deficiency.
Another 2020 study published in October in Seminars in Pediatric Neurology suggests that in many cases, the immune system produces antibodies that target the folate receptor alpha (FRα) on brain cells. These folate receptor autoantibodies (FRAA) block folate entry into the brain, resulting in low brain folate levels even when blood levels are normal. While only about 5–10% of the general population carries these antibodies, research suggests that 50–70% of children with autism may have them. This disruption is thought to significantly affect speech and cognitive development.
However, Dr. David Mandell, a professor of psychiatry and autism expert at the University of Pennsylvania, told Reuters that leucovorin might well be a possible treatment for some children with autism, "but the evidence we have supporting it... is really, really weak."
Credits: X
While TrumpRx is making headlines for lowering the prices of popular weight loss drugs, something else has also grabbed attention of many. A video from the Oval Office from the Thursday Press Conference when President Donald Trump was announcing the deal with the drugmakers, a man had collapsed. Many claimed that the person who collapsed was Gordon Findlay, who is Novo Nordisk's executive. Dr Mehmet Oz, an American present and a physician was swift to check on the man who had collapsed. Independent journalist Eric Daugherty shared the video and wrote: "A man just passed out during President Trump's Oval Office announcement. Dr Oz Sprung into action and assisted him. Pray for him."
Also Read: TrumpRx: Will Trump’s New Website Make Prescription Drugs More Affordable?
The reason why many have identified the man as Gordon Findlay because in the video, David Ricks, CEO of Eli Lily could be heard asking, "You okay? Gordon, you okay?" Upon this, the White House Press Secretary Karoline Leavitt said in the statement that "a representative with one of the companies fainted". However, no names were given.
Novo Nordisk later clarified the claims, and in a statement to Newsweek, the company said, "Please be aware that CEO Mike Doustdar and EVP, US operations, Dave More were the only two Novo Nordisk representatives in the Oval Office."
Dr Oz had previously also helped out at the Oval office in April, when a child fainted while he was being sworn in. A woman, who many media outlets claimed, appeared to be Oz's daughter, Daphne, escorted the girl who had fainted. Later, the White House official confirmed to Fox News Digital that the girl was family member of Oz and had recovered.
If someone collapses in front of you, the first need is for someone to try simple CPR or cardiopulmonary resuscitation, while medical help is on its way. What must one keep in mind if someone collapses?
Check for any danger around the person, and give the shoulders of the person who collapsed a shake. Ask them if they can hear you, notes BBC.
If there is no response, tilt their head back to ensure that the airway is clear. This may be enough for the person to again start breathing.
If they are not breathing, this is when CPR becomes important.
Also Read: Trump Strikes Agreement To Cut Costs of Popular Weight Loss Drugs: All You Need to Know
As per NHS, UK, there are two correct ways to practice CPR on adults:
This is to be carry out as a chest compression
Credits: AP and Canva
Ozempic is about to go on sale! With TrumpRx, a website announced by the US President Donald Trump will allow Americans to buy popular weight loss drugs at a cheaper rate. The drugmakers Eli Lilly and Novo Nordisk have agreed to match prices to the lowest paid in peer nations for all their drugs in Medicaid and for the list prices when their medications first hit the market. They will be offering primary care medicines that will reach to customers directly at a discounted price.
While popular weight loss drugs could be bought from the website at as lowest as $149 per month, what else does TrumpRx offer?
In his own words, "By taking this bold step, we are ending the era of global price gouging at the expense of American families."
Not just Novo Nordisk and Eli Lilly, in fact, it was Pfizer, which is the first US pharmaceutical group that signed up to the website. The company said that it would offer discounts of up to 85%. This is for the medicines for those not using health insurance policies to pay and for those on the government's low-cost insurance programme - Medicaid.
The plan is to launch the website in early 2026 from where consumers could buy prescribed medicines directly from pharmaceutical companies without having to go through insurance. This is also to aid those under the Medicaid programme, which is a federal government programme for adults and children from lower-income backgrounds. The beneficiaries will have access to the drugs at a discounted prices, which is closer to those paid by national health services in foreign countries, known as the "most favoured nation" prices.
"Most Favoured Nation" or MFN prices are those that the national health services in countries including Canada, France, Germany, Italy, Japan, the United Kingdom, Switzerland and Denmark pay the US pharmaceutical companies for prescribed drugs.
Since these medicines are exported in a bulk, the prices are lowered as the purchasing power is greater to demand of the ordinary consumers. This is why pharmaceutical companies tend to sell their drugs at a lower price outside than in their own country. Earlier this year in May, Trump, thus signed an executive order that aimed at reducing prescription drug prices in the US. He stated, "The United States will no longer subsidise the health care of foreign countries.”
Apart from the lower drug prices of popular weight loss drugs, Trump, in July had sent letters to CEOs of 17 pharmaceutical companies and ordered them to reduce their prices, based on certain promises from his end, which included:
Manufacturers will be provided with an avenue to cut out middlemen and sell medicines directly to patients
Manufacturers will be supported by trade policy in raising prices internationally
Trump had also announced new 100% tariffs on imported, branded pharmaceutical products, which will allow him to deliver the second promise.
As per a 2022 study commissioned by the Office of the Assistant Secretary for Planning and Evaluation, which is published on the US government website, the standard insulin prices in the US are 10 times higher than the prices in 33 OECD countries (Organisation for Economic Cooperation and Development). Lowering of the prices of drugs domestically, and removing the middle men could bring the prices down.
The study also found that the average gross prices in US were more than 10 times the price in France, and the United Kingdom. The prices further skyrocketed by nine times in Italy, eight times the prices in Japan, seven times the prices in Germany, and more than six times in Canada.
While many people who take insulin already pay a "net price", which is lower than the standard price, however, the net price is still 2.33 times the price paid in other countries.
TrumpRx, thus, could benefit anyone who buys drugs directly from the website. This is especially for those who do not have a health insurance in the US. As per a 2024 report from the US Census Bureau, around 8%, which makes 26 million of the US population, do not have a health insurance.
Apart from Eli Lilly and Novo Nordisk's popular weight loss drugs like Zepbound, Ozempic and Wegovy, Pfizer too has shared a list of primary-care medicine, not limited to the following:
Credits: PTI
TrumpRx: US President Donald Trump had announced this week that his administration plans to roll out a new website, called TrumpRx, which will allow Americans to purchase prescription medications from pharmaceutical companies at discounted rates.
In a major step to address rising drug costs, the Trump administration also unveiled agreements with Eli Lilly and Novo Nordisk to reduce prices for popular GLP-1 medications like Ozempic, Wegovy, and Zepbound. These deals, part of the TrumpRx initiative, are expected to make the drugs more affordable for Medicare, Medicaid, and direct consumers starting in 2026.
TrumpRx is an online platform designed to let consumers buy prescription medicines directly from the manufacturers, bypassing insurance intermediaries. The website is scheduled to launch in early 2026. Users will be able to search for the specific drug they need and be directed to the drug’s manufacturer, according to USA Today. The platform will offer prices closer to what national health services pay in other countries, following the principle of “most favoured nation” pricing. Medicaid beneficiaries—federal insurance for low-income adults and children—will also have access to the platform.
Also Read: Trump Strikes Agreement To Cut Costs of Popular Weight Loss Drugs: All You Need to Know
The website is part of a broader effort by Trump to curb high prescription drug costs in the US. In July, he sent a letter to the CEOs of 17 pharmaceutical companies demanding lower prices.
In the letter, he outlined several key points:
Anyone looking to buy prescription drugs directly from manufacturers, rather than through insurance, could benefit. A 2024 US Census Bureau report noted that 8% of Americans (about 26 million people) lacked health insurance in 2023, meaning they could significantly benefit from lower prices. Medicaid may also benefit, as its deal with Pfizer offers better pricing terms. Details about how this part of the program will work are not fully clear yet. Since most Americans rely on insurance for healthcare, experts believe initial adoption of the site may be limited.
On Thursday, President Trump announced deals with Novo Nordisk and Eli Lilly to cut costs for the lowest doses of their popular weight-loss drugs, lowering barriers for new patients seeking treatment. Beyond government programs, the same GLP-1 drugs will be available directly to consumers via TrumpRx.gov, launching in January 2026.
The starting doses of injectable Wegovy and Zepbound will cost $350 per month but are expected to trend down to $245 over two years. Oral versions, including Novo Nordisk’s upcoming semaglutide pill and Eli Lilly’s orforglipron, will start at $149 per month once approved.
© 2024 Bennett, Coleman & Company Limited